Lexicon Pharmaceuticals has announced management additions directed toward the completion of phase III development and commercial preparations for telotristat etiprate in carcinoid syndrome and preparation for phase III initiation and commercial readiness for sotagliflozin (LX4211) in type 1 diabetes.
Kenneth B. Kassler-Taub, M.D., has joined Lexicon as vice president of clinical operations, with responsibility for managing the execution of all of the company's clinical trials. Kassler-Taub brings to Lexicon more than 25 years' experience, most recently with Becton Dickinson and Company, where he was vice president, corporate clinical development overseeing the clinical development function company-wide, and where he earlier was worldwide vice president, medical affairs, BD Medical Segment. Previously, Kassler-Taub worked for 14 years at Bristol-Myers Squibb, where he worked in a series of roles including vice president, global pharmacovigilance, epidemiology and risk management, global clinical sciences and vice president, clinical affairs, worldwide clinical R&D.
Kiernan A. Seth, Ph.D., MBA, has joined Lexicon as executive director of marketing with responsibility for helping advance Lexicon's commercial readiness. Seth brings to Lexicon more than 19 years' experience. His most recent experience was from Eisai, where he was executive director, Eisai Value Maximization Systems and head of the oncology business unit. Previously, Seth worked in a series of marketing roles with Bristol-Myers Squibb, Pfizer and Schering-Plough involving products in oncology, cardiovascular and metabolic disease, immunology and central nervous system disorders. Seth will report directly to John Northcott, Lexicon's vice president of marketing, commercial strategy and operations.